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Imaging may be used in the diagnosis of a tumour, staging
both local disease, lymph node involvement and distant
metastases and may be requested in order to answer
a specific clinical question in an individual patient. It is
also used to measure therapeutic response to
radiotherapy and chemotherapy and in the detection of
tumour relapse. One important impact of the use of
sophisticated imaging techniques to stage patients with
cancer is the apparent continuous improvement in cancer
survival rates reported over the last 25 years. Although
this is easily attributable to earlier diagnosis and new and
more effective treatments, the effect of more accurate
staging may to some extent explain these improved results
[1, 2]). These authors showed that improved survival rates
were mainly an artefact of better staging; patients in the
lower stages with clinically occult (usually nodal) disease
were being identified with better imaging and were being
placed in a more advanced stage (stage 'migration'). This
improved staging led to benefit to all groups; in the lower
stages patients with occult metastases would be removed
with benefit to those stages; in the higher stages those
patients with a lower tumour burden would be added to
those with a higher one with improvement in survival
rates. Thus, while individual prognosis did not change
overall, survival in each stage improved. The stage
migration phenomenon occurs when comparisons are
made between groups of patients who have undergone
less or more thorough staging techniques and therefore
occurs when comparisons are made over a time period
during which new imaging technology has been
introduced.
In order for a local treatment such as surgery or
radiation therapy to be effective and result in a cure the
tumour must be truly localised without any spread to
lymph nodes or distant organs. One of the key issues
which therefore occupies both clinician and radiologists
together is which imaging modality provides the best
diagnostic performance in detecting local invasion and
metastatic disease for an individual tumour site.
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The effective management of patients with cancer requires a multidisciplinary team approach with regular dialogue between
the specialist cancer surgeon, oncologist, diagnostic radiologist and histopathologist to decide on the choice of treatment for
each individual patient. The diagnostic radiologist plays an extremely important role in that team in advising on the role of
imaging for each particular tumour site and for a proper evaluation of images for staging of the local tumour and lymph nodes
and distant metastases. This guest lecture will focus on the impact of imaging on the treatment choice for localised tumours,
looking first at the significance of the findings of a radiological investigation and then the impact of imaging on management
of lung cancer and breast, prostate and cervical cancer as illustrations. 
Znaczenie diagnostyki obrazowej dla wyboru metody leczenia w przypadku nowotworów 
o zaawansowaniu miejscowym
Skuteczne leczenie chorego z nowotworem wymaga podejÊcia wielodyscyplinarnego. W toku post´powania konieczna jest sta∏a
wymiana informacji pomi´dzy chirurgiem onkologiem, radiologiem i histopatologiem. Umo˝liwia to indywidualne dobranie
post´powania - inne pod kàtem ka˝dego przypadku. Radiolog - specjalista w zakresie diagnostyki obrazowej pe∏ni bardzo
istotnà funkcj´; doradza techniki obrazowania optymalne przy danej lokalizacji guza i pomaga oceniç uzyskane obrazy, co z
kolei u∏atwia okreÊlenie stopnia zaawansowania nowotworu, stan w´z∏ów ch∏onnych i ewentualnà obecnoÊç odleg∏ych
przerzutów. Poni˝sza praca poÊwi´cona jest znaczeniu metod obrazujàcych w diagnostyce zmian nowotworowych. Omówione
zosta∏y mo˝liwoÊci diagnostyczne oraz wp∏yw wyników uzyskanych dzi´ki technikom obrazujàcym na post´powanie
terapeutyczne na przyk∏adzie chorych z rakiem p∏uca, piersi, prostaty i szyjki macicy.
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The choice of imaging modality will depend on the
diagnostic performance of a particular technique to
identify the disease correctly. This diagnostic performance
is a measure of sensitivity (the ability of an investigation to
identify correctly those patients who have the disease),
and specificity (the ability of an investigation to identify
correctly those patients who do not have the disease),
both of which are independent of disease prevalence and
called the 'intrinsic operating characteristics' of the test. In
contrast, the positive predictive value (the probability of
whether the disease is actually present if the test is
positive) and the negative predictive value (whether the
disease is likely to be absent if the result is negative) and
accuracy (combined sensitivity and specificity) are highly
dependent on the prevalence of the disease. Reports of
sensitivity and specificity of an imaging modality are
therefore more reliable than PPV and accuracy, which
are greatly influenced by regional variation of disease
prevalence. However, in spite of knowledge of the best
diagnostic performance of an imaging modality, other
practical variables such as availability and cost of
equipment, expertise and workload of an imaging team
and department and patient compliance, may mean that
the optimum imaging practice may not always be feasible
in an individual patient situation.
A receiver-operator characteristic (ROC) curve is
a plot showing a relationship between sensitivity and
specificity for different cut-off points of a particular test.
As the criteria for calling a test positive become more
stringent specificity improves and sensitivity decreases.
As the criteria are relaxed, sensitivity improves while
specificity diminishes. The fundamental principle
illustrated by the ROC curve is that there is an inherent
limit to the diagnostic efficacy of the test. Once this limit
has been reached, the interpreter can only improve
sensitivity at the expense of specificity and vice versa.
The ROC curve can therefore be used to select the 'best'
cut-off criteria for positivity taking the positive predictive
value and the relative costs in terms of patient outcome
of false positive and false negative test results into
account. Close collaboration between radiologist and
oncologist is therefore essential to interpret the results of
imaging in staging cancer, the choice of imaging for
different tumour types, protocols and timing of imaging in
relation to treatment and protocols for follow up of
treatment.
Lung Cancer
Computed tomography has become the imaging modality
of choice in the evaluation of patients with lung cancer
and is useful for detecting metastases in the liver and
adrenal glands, as well as determining the local extent of
the primary tumour as a guide to surgical management
and radiotherapy target volume (GTV). The technical
resectability of the primary tumour is determined by the
T stage. T3 tumours may cross the pleural space to
involve the parietal pleura or may invade the chest wall or
extend in limited fashion within the mediastinum, but
remain operable using more complex techniques.
Conventionally T4 tumours are irresectable because of
the invasion of critical mediastinal structures such as the
heart, major vessels, oesophagus or carina. The distinction
therefore between T3 and T4 disease is critical reflecting
the dividing line between conventional surgical and non-
surgical management.
There are several pitfalls in the interpretation of CT
images in determining the extent of the primary tumour.
Firstly, separating the tumour from peripheral con-
solidation in the lung can be difficult. Distal collapsed
lung has been shown to enhance more than central
tumour [3]. A tumour mass results in expansion and
a convex shape configuration whereas atelectasis produces
contraction and a concave configuration; consolidation
produces no change [4]. Caldwell et al in Toronto have
studied the impact of PET scanning information on the
inter-observer variation in GTV delineation and have
shown that PET reduces this variability, partly due to its
ability to distinguish tumour from adjacent atelectasis
[5].
The value of CT in the determination of chest wall
invasion is somewhat limited. Only the presence of rib
destruction or tumour extending outside the chest wall are
reliable signs of chest wall invasion [6]. Hence, both CT
and MRI can predict resectable tumours but may fail to
distinguish inflammatory chest wall adherence from early
invasion. Extensive chest wall disease is readily identified
by either modality but may not imply inoperability. Glazer
et al correlated three features of lung tumour with
operative findings and showed that (i) less than 3cm of
mediastinal contact (ii) maintained fat plane of separation
from the mediastinum (iii) less than 90° of circumferential
aortic contact are key features [7]. The presence of
at least one of these features predicted resectability in
36 out of 37 cases with mediastinal contact. However,
criteria for non-resectability are harder to identify and
this is unfortunately the information required by the
surgeon.
MRI is of undoubted benefit in the special situation
of superior sulcus tumours where it can not only diagnose
chest wall invasion but also show extension into the root
of the neck with visualisation of vascular and neural
structures [8].
The appearance of the CT image used for delinea-
tion of the GTV can be varied by the CT window display
settings. Soft tissue window settings are most appropriate
for imaging of central structures such as mediastinal
nodes. However, it has been shown that for pulmonary
nodules the lung settings are the most accurate as shown
in one study by Harris et al which used lung settings of
width 850HU and level -750HU [9]. The detection of
lymph node involvement using CT relies on the criteria of
size and a short axis greater than 1cm is usually taken as
the cut-off for positive tumour involvement. However,
moderate enlargement may be due to reactive hyperplasia
or distal infection or other inflammatory lung conditions
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and one study has shown that 37% of mediastinal nodes
in the range 2-4cm were tumour free from lung cancer
[10].
CT is the standard method for diagnosing nodal
enlargement and has been extensively evaluated. Pitfalls
in diagnosis for the clinician include partial volume effect
and mistaking vascular structures such as the azygos vein
for mediastinal lymph nodes. The value of CT is that if it
shows extensive nodal metastases then inappropriate
surgery can be avoided. If the CT scan is negative for
mediastinal adenopathy then either a PET scan should be
performed or mediastinoscopy performed prior to surgery
or nodal sampling at surgery. If CT shows enlarged lymph
nodes only then a biopsy is essential to obtain histological
tissue before the patient is denied the chance of surgical
cure because of the preponderance of enlarged reactive
nodes.
Positron Emission Tomography (PET) with FDG
has become a useful imaging modality in evaluating
patients with lung cancer. It takes advantage of increased
glucose metabolism by malignant cells so that tumour
masses take up increased amounts of FDG relative to
normal lung tissue. Several studies have shown that up to
18% of patients considered to be resectable by
conventional imaging will have more advanced disease
demonstrated by PET scanning and become non-
resectable. PET scanning is particularly helpful in staging
lymph node disease where it has a sensitivity of 79% and
specificity of 91%, much increased over CT scanning.
With a negative predictive value of 95% the surgeon
knows that if the PET scan is clear the patient is likely to
be operable. However, the positive predictive value is
only 80% which means that mediastinoscopy and biopsy is
still necessary in case PET scan has created a false
positive result due to inflammation. Biopsy is essential
in order to ensure that the patient is not denied curative
surgery due to a false positive result [11]. Kalff et al have
prospectively studied the impact of PET on the changing
stage of 59 patients with lung cancer and have shown that
it not only up-stages patients with stage I, II and III
disease, but also down-stages patients with stage III and
IV disease leading to more appropriate choice of patients
for curative surgery [12].
In summary, the impact of imaging for lung cancer
is that CT is the imaging modality of choice and can
be used to predict resectable tumours but is unreliable
for identifying inoperable mediastinal invasion. MRI is
comparable with CT but is reserved for problem solving
situations such as superior sulcus tumours. PET scanning
improves lymph node staging but where it is unavailable
CT with mediastinoscopy can provide similar information.
The liver and adrenal glands can be conveniently imaged
at the same time as chest CT for the detection of
asymptomatic metastases. Further imaging studies in the
asymptomatic patient depends on patient selection.
Van de Steene et al have shown a large inter-
observer variation in definition of GTV for lung cancer in
a recent study where five clinicians were asked to define
the GTV on planning CT scans of 8 patients [13].
A further study by Giraud et al looked at the inter-
observer variability of GTV in 10 patients with lung
cancer shown between radiation oncologists and
radiologists [14]. Significant differences in site and size of
the GTV were observed with radiologists delineating
smaller GTVs than oncologists and experiencing less
difficulty with difficult cases. The reasons for discrepancy
were failure to identify atelectasis and pleural thickening
correctly and poor knowledge of radiological anatomy.
Multidisciplinary co-operation and teaching of ICRU
definitions and interpretation of CT scan images would all
improve GTV delineation. Joint delineation of the GTV
with radiologists and senior and junior clinicians would be
an advantage. The role of PET/CT fusion remains under
evaluation.
Breast Cancer
Mammography is still the most widely used method for
diagnosing breast cancer supplemented by ultrasound.
However, it has a false negative rate of 4-34%. Recently
rapid progress has been made with MRI in its diagnostic
potential, including the use of dynamic MRI. MRI is still
in a state of development and indications for MRI
imaging are still unclear and protocols vary considerably
between different institutions. Image interpretation is
also under development and at present there are not
internationally accepted criteria for the interpretation
of breast MRI images. There have been two major
approaches: evaluation of lesion morphology and
assessment of dynamic contrast enhancement patterns.
Using dynamic contrast enhanced sequences the sen-
sitivity for tumour detection has been reported between
90 and 100%. However, specificity has not been as
impressive with reported rates of 37-85%. It is likely that
a combination of dynamic and morphological sequences
will improve on this specificity. The main role of MRI is in
delineating multicentric disease but whilst MRI is
sensitive in detecting invasive cancer, lobular tumours
are less well defined. It is less sensitive for detecting DCIS
than for invasive cancer and microcalcification is poorly
seen with MRI.
MRI is better at defining the size of the primary
tumour than mammography (95% versus 75%) and this
may have a role in the selection of patients for breast
conserving surgery where the upper limit is 4cm. The
ability of MRI to detect multicentric disease leads to the
selection of patients for mastectomy but, at the moment,
biopsy under MRI control remains difficult. MRI is also
good for assessing suspected local recurrence in the breast
following radiotherapy but false positives may occur
within the first nine months after treatment.
Prostate Cancer
The aim of local staging is to select out those patients
with organ confined prostate cancer for radical prosta-
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tectomy, brachytherapy or external beam radiotherapy
as curative treatment from those in whom the cancer is no
longer contained within the prostate gland. Magnetic
resonance imaging has become the most accurate method
for evaluating the prostate gland with reported staging
accuracies of 80-90%. Either phased array, pelvic coils
or dedicated endorectal coils can be used and MRI
scanning should preferably be avoided for two to three
weeks after prostatic biopsy. Prostate cancers are best
identified on T2 weighted scans with the normal
peripheral gland shown as high signal intensity and
cancers shown as areas of low signal intensity. MRI is
the best imaging method for diagnosing seminal vesicle
involvement with accuracy rates of 65-90%. Accuracy
rates of 58-90% are reported for diagnosis of T3 disease
with extension "through the capsule" of the prostate.
Future developments in MRI such as dynamic contrast
enhancement and MR spectroscopy will further refine
the areas of active tumour within the prostate gland and
help to improve GTV definition. MRI and CT offer
similar levels of accuracy in the detection of pelvic
lymphadenopathy with CT having the advantage that fine
needle aspiration cytology can be performed more easily
for confirmation of disease.
Evaluation of regional nodes is performed as part
of the staging process and is particularly important in
patients who are candidates for radical prostatectomy,
since positive nodes make surgery inappropriate.
Laparoscopic pelvic lymph node dissection is less invasive
than open pelvic surgery and almost as accurate in
sampling lymph nodes (90%). However, this method
requires skill and experience and if no lymph nodes
metastases are found a second operation is necessary
unless frozen section or FNA interpretation is highly
reliable. Computed tomography scanning of the prostate
is not diagnostically useful because it does not show
internal prostate anatomy nor tumour within the gland. It
also over-estimates the volume of the prostate gland
compared with MRI and studies are on-going to provide
CT-MR image fusion for more accurate delineation of
the GTV [15]. Modern ultrasound equipment used for
transrectal ultrasound provides excellent images of the
prostate and its internal architecture. Its main application
is in prostate brachytherapy where it can be used for CTV
definition and to guide the treatment process itself. The
entire prostate gland is the CTV for planning purposes
and where the tumour is visualised this information can
be taken into account for dosimetry.
Cervical Cancer
The most important aspect of staging in cervical cancer is
an assessment of the possibility of parametrial invasion.
Patients without evidence of parametrial invasion are
treated with radical hysterectomy whereas when there is
radiological evidence that parametrial invasion is present
patients are treated with radiotherapy. The identification
of disease less than or equal to stage IIA is therefore
critical. The overall accuracy of MRI in staging cervical
cancer is 76-83%, compared with 70% for clinical staging
and 63% for CT [16]. Comparative studies reported that
the accuracy for parametrial invasion was 78% for clinical
evaluation, 70% for CT and 92% for MRI [17]. Using
MRI 95% of stage IB tumours can be identified.
Preservation of the outer low signal intensity ring of the
cervical stroma on T2 weighted images reliably indicates
that tumour is confined to the cervix and no parametrial
spread has occurred. However, disruption of the outer
ring does not always indicate tumour extension into the
parametrium and false positive results occur, particularly
with large exophytic tumours and in the presence of
peritumoural inflammation. The sensitivity of MRI in
detecting vaginal invasion (stage IIA disease) is excellent
with an accuracy of up to 93%. In stage IIB disease there
is extension of tumour into the parametrium best seen
on axial T2 weighted images. Preservation of the
hypodense stromal ring is a reliable sign of intact
parametrium. This sign has a very high specificity, almost
100%, and is of great value in the exclusion of parametrial
invasion. The clinical value of MRI in staging carcinoma
of the cervix lies in its extremely high negative predictive
value for parametrial invasion on which the decision
regarding the need for hysterectomy can be based. The
loss of the low signal intensity ring has a lower specificity
and positive predictive value of about 85% for
parametrial invasion.
In patients with early stage carcinoma of the cervix
the standard treatment of hysterectomy results in sterility.
However, a new surgical procedure called a trachelectomy
preserves the uterine body with excision of tumour within
the cervix and maintenance of fertility. The key to
determining the operability for this procedure is assessing
the proximal extent of the tumour into the uterine body.
MRI is able to predict the proximal extent of the cervical
cancer into the myometrium and its relationship to the
internal os ([18].
As MRI has been showed to provide such an
accurate depiction of the size and extent of cervical
tumours it follows that it is widely suited to planning
radiotherapy treatment. Two large studies have shown
that the introduction of MRI led to a change in position
of portals in 50-70% of patients [19-21]. Both studies
conclude that when treating carcinoma of the cervix
standard protocols do not exist and the design of lateral
fields has to be based on tumour anatomy as delineated
using MRI. Individually shaped fields based on MRI
scans could better encompass the PTV and spare
avoidable radiation to normal tissues. No study has yet
been reported on the implementation of MR images in
a planning system in the design of radiation treatment
of carcinoma of the uterine cervix.
There is no doubt that regular multidisciplinary team
meetings with review of imaging and histopathology and
discussion with colleagues of individual patient's tumour
presentations is the best way to provide optimum
management of patients with cancer. These discussions
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not only clarify decision making for the individual patient
but act as stimulus to areas of research and education
for all members of the team.
H Jane Dobbs MD
Guy's, King's & St Thomas' Cancer Centre
Guy's & St Thomas' Hospital
Lambeth Palace Road
London SE1 7EH UK
UK
References
1. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage
migration and new diagnostic techniques as a source of misleading
statistics for survival in cancer. New Engl J Med 1985; 312: 1604-8.
2. Bosi GJ, Geller NL, Chan EY. Stage migrations and increasing proportion
of complete responders in patients with advanced germ cell tumours.
Cancer Research 1988; 48: 3524-7.
3. Onitsuka H, Tsukuda M, Araki M et al. Differentiation of central lung
tumour from post-obstructive lobar collapse by rapid sequence computed
tomography. J Thorac Imaging 1991; 6: 28-31
4. Bourgouin PM, McCloud TC, Fitzgibbon JF et al. Differentiation of
bronchogenic carcinoma from post-obstructive pneumonitis by MRI.
J Thorac Imaging 1991; 6: 22-7.
5. Caldwell CB, Mah K, Ung YC et al. Observer variation in contouring
gross tumor volume in patients with poorly defined non-small-cell lung
tumors on CT. The impact of 18FDG-hybrid PET fusion. Int J Radiat
Oncol Biol Phys 2001; 51: 923-31.
6. Webb WR, Gatsonis C, Zerhouni E et al. CT and MR imaging in staging
non-small cell bronchogenic carcinoma: report of the Radiology
Diagnostic Oncology Group. Radiology 1991; 178: 705-13.
7. Glazer GM, Oringer MB, Gross BH et al. The mediastinum in non-small
cell cancer: CT-surgical correlation. Am J Radiol 1984; 142: 1101-5.
8. McLoud TC, Filion RB, Edelman RR et al. MR imaging of superior
sulcus carcinoma. J Comput Assist Tomogr 1989: 13: 233-9.
9. Harris K, Adams H, Lloyd D. and Harvey D. The effect on apparent
size of simulated pulmonary nodules of using three standard CT window
settings. Clin Radiol 1993: 47: 241 -
10. McLoud TC, Bourgouin PM, Greenberg RW et al. Bronchogenic
carcinoma: analysis of staging in the mediastinum with CT by correlative
lymph node mapping and sampling. Radiology 1992; 182: 319-23.
11. Dwamena BA, Sonnad SS, Angobaldo JO et al. Metastases from non-
small cell lung cancer: mediastinal staging in the 1990s – meta-analytic
comparison of PET and CT. Radiology 1999; 213: 530-6.
12. Kalff V, Hicks R, MacManus M et al. Clinical impact of 18F Fluoro-
deoxygluscose positron emission tomography in patients with non-small-
call cancer: a prospective study. J Clin Oncol 2001; 19: 111-8.
13. Van de Steene J, Linthout N, de Mey J et al. Definition of gross tumor
volume in lung cancer: inter-observer variability. Radiat & Oncology 2002;
62: 37-49.
14. Giraud P, Elles S, Helfre S et al. Conformal Radiotherapy for Lung
Cancer: Different delineation of the gross volume (GTV) by radiologists
and radiation oncologists. Radiother & Oncol 2002; 62: 27-36.
15. Rasch C, Barillot I, Remeijer P et al. Definition of the prostate in CT and
MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 1999; 43: 57-66.
16. Kim SH, Choi BI, Lee HP et al. Uterine cervical carcinoma: comparison
of CT and MRI findings. Radiology 1990; 175: 45-51.
17. Kim SH, Choi BI, Han JK et al. Preoperative staging of uterine cervical
carcinoma: comparison of CT and MRI in 99 patients. J Comput Assist
Tomogr 1993; 17: 633-40.
18. Peppercorn PD, Jeyarajah AR, Woolas R et al. Role of MR imaging in the
selection of patients with early cervical carcinoma for fertility-preserving
surgery: initial experience. Radiology 1999; 212: 395-9.
19. Zunino S, Rosao O, Lucino S et al. Anatomic study of the pelvis in
carcinoma of the uterine as related to the box technique. Int J Radiation
Oncol Biol Phys 1999; 44: 53-9.
20. Thomas L, Chacon B, Kind M et al. Magnetic resonance imaging in the
treatment planning of radiation therapy in carcinoma of the cervix treated
with the four-field pelvic technique. Int J Radia Oncol Biol Phys 1997;
37: 827-32.
21. Ahed S, Nutting CM, Reznek R et al. The impact of MRI in radiotherapy
planning for cervix cancer. Clin Oncol 2001; 13: 318-9.
Paper received and accepted 23 June 2003
